Edwards Lifesciences’ RESILIA data may shift the valve debate, but not without caveats
Valve durability is becoming a lifetime-care question. Edwards Lifesciences’ 10-year RESILIA data raise the stakes for heart teams.
Why Edwards Lifesciences is betting on transcatheter replacement to solve tricuspid regurgitation
Find out how transcatheter tricuspid valve replacement is reshaping treatment options for severe regurgitation and what clinicians are watching next.
Edwards Lifesciences’ SAPIEN M3 FDA approval marks a turning point for transseptal mitral valve therapy
Edwards Lifesciences’ SAPIEN M3 becomes the first FDA-approved transseptal mitral valve replacement system. Explore how it reshapes TMVR in 2026.